<?xml version="1.0" encoding="UTF-8"?>
<aggregateKnowledgeResponse xmlns="http://www.w3.org/2005/Atom">
	<feed>
		<title>Management of vesicoureteral reflux</title>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0808232" scheme="gov.nih.nlm.semanticType.topp" label="Therapeutic interventions"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="Medical therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="Antimicrobial"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
		<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3540018" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonamides, trimethoprim"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedures"/>
		<category term="C0348025" scheme="gov.nih.nlm.semanticType.topp" label="invasive procedures"/>
		<category term="C1970989" scheme="gov.nih.nlm.semanticType.topp" label="bladder catheterization"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0021107" scheme="gov.nih.nlm.semanticType.topp" label="implantation"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0442967" scheme="gov.nih.nlm.semanticType.topp" label="salvage"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0282493" scheme="gov.nih.nlm.semanticType.topp" label="endoscopic surgery"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0150474" scheme="gov.nih.nlm.semanticType.topp" label="bladder training"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C1572381" scheme="gov.nih.nlm.semanticType.phsu" label="no data"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="Prophylactic antibiotic therapy"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="cotrimoxazole"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="prophylactic antibiotic therapy"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="Medical therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="prophylactic antibiotic therapy"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="Surgical"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0374711" scheme="gov.nih.nlm.semanticType.topp" label="surgical repair"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="document"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="prophylactic antibiotic therapy"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<id>6095</id>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H2"/>
			<id>210484</id>
			<summary>
				<section label="THERAPEUTIC INTERVENTIONS" id="2">
					<fragment>Management of vesicoureteral reflux (VUR) is principally based upon the following: Identification of children with VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H2"/>
			<id>210488</id>
			<summary>
				<section label="THERAPEUTIC INTERVENTIONS" id="2">
					<fragment>Identifying and managing children with bladder and bowel dysfunction.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H2"/>
			<id>210489</id>
			<summary>
				<section label="THERAPEUTIC INTERVENTIONS" id="2">
					<fragment>Therapeutic interventions include medical therapy (ie, antibiotic prophylaxis), treatment of comorbid conditions such as voiding dysfunction, and surgical correction.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C0808232" scheme="gov.nih.nlm.semanticType.topp" label="Therapeutic interventions"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H2"/>
			<id>210490</id>
			<summary>
				<section label="THERAPEUTIC INTERVENTIONS" id="2">
					<fragment>Clinical trials comparing the two approaches demonstrate a decrease in the incidence of pyelonephritis with surgical intervention, but no significant difference in the risk of developing subsequent new renal scars, hypertension, or chronic kidney disease.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H10343204"/>
			<id>210491</id>
			<summary>
				<section label="Medical treatment" id="10343204">
					<fragment>Medical therapy for VUR consists of daily prophylactic administration of antibiotics.</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="Medical therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H10343204"/>
			<id>210493</id>
			<summary>
				<section label="Medical treatment" id="10343204">
					<fragment>Antimicrobial agents most commonly used for prophylaxis include trimethoprim-sulfamethoxazole, trimethoprim alone, or nitrofurantoin.</fragment>
				</section>
			</summary>
			<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="Antimicrobial"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H10343204"/>
			<id>210496</id>
			<summary>
				<section label="Medical treatment" id="10343204">
					<fragment>Amoxicillin and cephalosporins are not recommended because of the increased likelihood of resistant organisms, except in infants below two months of age.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H10343204"/>
			<id>210497</id>
			<summary>
				<section label="Medical treatment" id="10343204">
					<fragment>Adverse effects of sulfonamides, trimethoprim, or nitrofurantoin preclude their use in infants less than two months of age.</fragment>
				</section>
			</summary>
			<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3540018" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonamides, trimethoprim"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H10343204"/>
			<id>210500</id>
			<summary>
				<section label="Medical treatment" id="10343204">
					<fragment>Other concerns related to medical therapy include compliance, breakthrough infection, and the need for monitoring of VUR by either contrast voiding cystourethrogram (VCUG) or radionuclide cystogram (RNC).</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H10343204"/>
			<id>210501</id>
			<summary>
				<section label="Medical treatment" id="10343204">
					<fragment>VCUG and RNC are both invasive procedures that require bladder catheterization.</fragment>
				</section>
			</summary>
			<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedures"/>
			<category term="C0348025" scheme="gov.nih.nlm.semanticType.topp" label="invasive procedures"/>
			<category term="C1970989" scheme="gov.nih.nlm.semanticType.topp" label="bladder catheterization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H10343204"/>
			<id>210504</id>
			<summary>
				<section label="Medical treatment" id="10343204">
					<fragment>In one study of 51 low-risk (no voiding abnormalities or renal scarring) older children (mean age 8.6 years) with grades I to IV VUR, cessation of prophylactic antibiotics resulted in no new renal scarring measured one year later by dimercaptosuccinic acid (DMSA) renal scan.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H4"/>
			<id>210506</id>
			<summary>
				<section label="Surgical treatment" id="4">
					<fragment>The two surgical approaches used are open surgical reimplantation and endoscopic correction.</fragment>
				</section>
			</summary>
			<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H1918735"/>
			<id>210507</id>
			<summary>
				<section label="Open surgical reimplantation" id="1918735">
					<fragment>Open surgical reimplantation of ureters is a highly successful procedure, with reported correction rates of 95 to 99 percent regardless of the severity of VUR.</fragment>
				</section>
			</summary>
			<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H1918742"/>
			<id>210516</id>
			<summary>
				<section label="Robotic assisted laparoscopic reimplantation" id="1918742">
					<fragment>Two case series reported comparable success rates between children who underwent robotic assisted reimplantation compared with patients undergoing open surgical correction during the same time periods.</fragment>
				</section>
			</summary>
			<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H1918742"/>
			<id>210518</id>
			<summary>
				<section label="Robotic assisted laparoscopic reimplantation" id="1918742">
					<fragment>Further studies are needed to determine the relative cost/benefit of robotic assisted reimplantation versus open surgical reimplantation.</fragment>
				</section>
			</summary>
			<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210522</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>The STING procedure was modified to include submucosal injection in the distal ureter, which may require distention of the ureter with irrigating fluid, referred to as HIT (hydrodistention implantation technique).</fragment>
				</section>
			</summary>
			<category term="C0021107" scheme="gov.nih.nlm.semanticType.topp" label="implantation"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210531</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>Multiple regression analysis demonstrated that preoperative VUR grade was the single most important factor affecting outcome: Grade I: 89 percent (95% CI, 69-90 percent).</fragment>
				</section>
			</summary>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210539</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>The success rate of a second STING procedure after an initial failed injection appears to be good.</fragment>
				</section>
			</summary>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210543</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>The success rate for both initial and subsequent endoscopic correction is lower in patients with grade V reflux.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210544</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>This was illustrated in a case series of 132 children with grade V reflux, in whom VUR was completely resolved in 88 (53 percent) ureters and decreased in severity in 26 (16 percent) ureters after the first procedure, and in 36 (22 percent) and 10 (6 percent) after the second and third injection, respectively.</fragment>
				</section>
			</summary>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210546</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>The STING also has been utilized as a salvage procedure correcting VUR in 65 percent of patients who failed a previous open surgical reimplantation.</fragment>
				</section>
			</summary>
			<category term="C0035139" scheme="gov.nih.nlm.semanticType.topp" label="reimplantation"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="C0442967" scheme="gov.nih.nlm.semanticType.topp" label="salvage"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210547</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>Endoscopic correction has also been successfully used in patients with VUR associated with paraureteral diverticula (also known as Hutch diverticula).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210548</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>In contrast, endoscopic correction has not been successful in patients with refluxing megaureter with distal aperistaltic segments, and is less successful in those with bladder and bowel dysfunction.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210552</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>Ureteral obstruction - In a retrospective review of 745 patients with 1155 ureters who underwent correction, the incidence of postoperative ureteral obstruction was less than 1 percent of treated patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210553</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>Postprocedure urinary tract infection (UTI) and VUR recurrence - In a retrospective review of 167 children who underwent endoscopic correction, 40 patients (24 percent) developed a UTI at a median follow-up of 32 months postprocedure.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210554</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>One-half of these patients with UTIs were febrile with their infection.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210555</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>Repeat cystography was performed in 18 patients with postprocedure UTI (15 with fever and 3 without fever) and VUR was noted in seven patients, all of whom had febrile UTI.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210558</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>In this cohort, multivariate analysis demonstrated that febrile UTI was more likely in patients who were female and had bladder and bowel dysfunction (either pre- or postoperative).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210562</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>Although the rates of successful correction with the endoscopic approach STING do not yet approach that of an open procedure and the long-term outcome of the endoscopic approach is uncertain, the minimal invasiveness of the procedure makes it an attractive alternative for patients with less severe grades of reflux.</fragment>
				</section>
			</summary>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H6"/>
			<id>210563</id>
			<summary>
				<section label="Endoscopic correction" id="6">
					<fragment>As an example, in the Swedish Reflux Trial of 203 children between one and two years of age with VUR grade III to IV, there was a 71 percent resolution of VUR in those patients assigned to endoscopic correction.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25152771"/>
			<id>210565</id>
			<summary>
				<section label="Voiding dysfunction" id="25152771">
					<fragment>Voiding (bladder and bowel) dysfunction, referred to as bladder bowel dysfunction (BBD) in the 2010 revised American Urologic Association Guidelines, prolongs the time for VUR resolution, and is associated with an increased risk of breakthrough infection and reduced success of endoscopic surgery.</fragment>
				</section>
			</summary>
			<category term="C0282493" scheme="gov.nih.nlm.semanticType.topp" label="endoscopic surgery"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25152771"/>
			<id>210566</id>
			<summary>
				<section label="Voiding dysfunction" id="25152771">
					<fragment>These patients can have difficulties in both bowel and bladder elimination.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25152771"/>
			<id>210569</id>
			<summary>
				<section label="Voiding dysfunction" id="25152771">
					<fragment>In a cohort of 347 toilet-trained children with VUR from a single tertiary center, 298 patients underwent urodynamic evaluation as part of the standard practice evaluation at this institution.</fragment>
				</section>
			</summary>
			<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25152771"/>
			<id>210570</id>
			<summary>
				<section label="Voiding dysfunction" id="25152771">
					<fragment>There was a history of symptomatic lower urinary tract symptoms in 37 percent of the patients, who were younger, were more likely to have an urodynamic study demonstrating voiding dysfunction (particularly evidence of an overactive bladder), and had milder VUR than the overall cohort.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25152771"/>
			<id>210571</id>
			<summary>
				<section label="Voiding dysfunction" id="25152771">
					<fragment>In a baseline study, bowel and bladder dysfunction was identified in 56 percent of 126 toilet-trained children (&lt;6 years of age) enrolled in the randomized intervention for VUR (RIVUR) trial comparing antibiotic prophylaxis and placebo in children with grades I to IV VUR.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25152771"/>
			<id>210572</id>
			<summary>
				<section label="Voiding dysfunction" id="25152771">
					<fragment>Aggressive treatment with bladder training can both improve bladder function and lead to VUR resolution including some patients with grade V reflux.</fragment>
				</section>
			</summary>
			<category term="C0150474" scheme="gov.nih.nlm.semanticType.topp" label="bladder training"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H7"/>
			<id>210575</id>
			<summary>
				<section label="CHOICE OF THERAPY" id="7">
					<fragment>Historically, either medical or surgical intervention has been the recommended treatment in children with vesicoureteral reflux (VUR).</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H7"/>
			<id>210577</id>
			<summary>
				<section label="CHOICE OF THERAPY" id="7">
					<fragment>There are limited data comparing the effect of treatment versus no treatment (ie, surveillance) of VUR on renal outcome (ie, chronic kidney disease and renal scarring).</fragment>
				</section>
			</summary>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H7"/>
			<id>210578</id>
			<summary>
				<section label="CHOICE OF THERAPY" id="7">
					<fragment>In contrast, there are several clinical trials that demonstrate similar renal outcome in patients treated with either prophylactic antibiotics or surgical correction.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210579</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>A surveillance regimen and prompt treatment of intercurrent episodes of urinary tract infection (UTI) may be as effective as medical or surgical intervention in children with VUR, particularly in those with low-grade reflux (ie, grades I through II).</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210580</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>In particular, the premise that antimicrobial prophylaxis is more effective than surveillance in the prevention of recurrent UTI and acute pyelonephritis in children with VUR has been increasingly questioned.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210581</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>A meta-analysis of individual data in infants and young children (2 to 24 months) without VUR and with grades I to IV VUR did not detect an overall benefit for prophylaxis in preventing recurrent UTI.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210585</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>As an example, in patients with grade IV VUR, the risk of recurrent infection for patients treated medically versus by surveillance alone was 29 versus 43 percent, but did not differ statistically (relative risk 0.73, 95% CI 0.39-1.35).</fragment>
				</section>
			</summary>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210586</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>In addition, there were no data presented for patients with grade V VUR.</fragment>
				</section>
			</summary>
			<category term="C1572381" scheme="gov.nih.nlm.semanticType.phsu" label="no data"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210588</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>In patients with grade I to III VUR, several trials have reported no difference in the rate of UTI or renal scarring between medical intervention (prophylactic antibiotics) and surveillance as illustrated by the following studies.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210590</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>In the first unblinded study of 236 children between 3 months and 18 years of age with acute pyelonephritis (APN), 113 patients with mild VUR (grade I [n = 19], grade II [n = 57], and grade III [n = 37]), and 115 patients without VUR were randomly assigned to receive prophylactic antibiotics or no prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210591</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>Prophylactic antibiotic therapy in children with low-grade VUR did not decrease the recurrence of either cystitis or APN, or the rate of renal scarring.</fragment>
				</section>
			</summary>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="Prophylactic antibiotic therapy"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210593</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>In the second study of 225 children between one month and three years of age with grades I through III VUR, patients were randomly assigned to receive prophylactic cotrimoxazole or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="cotrimoxazole"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210594</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>There was no difference in the incidence of UTI and febrile UTI after 18-month follow-up between the overall groups who received prophylaxis or placebo (17 versus 26 percent) or in subgroups based upon the severity of their reflux.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210595</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>There appeared to be an association with gender, as prophylactic antibiotics reduced recurrent infection in boys, particularly those with Grade III reflux.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210596</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>These results suggest that prophylactic antibiotic therapy may prevent infection with higher grades of reflux, particularly in boys.</fragment>
				</section>
			</summary>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="prophylactic antibiotic therapy"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210597</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>In a third study of 338 patients with urinary tract infections, a subset analysis of the 128 patients demonstrated no difference in the rate of repeat febrile UTI in patients who received prophylactic antibiotics versus no prophylaxis (12 versus 20 percent).</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210599</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>the reduction in absolute risk was greatest for children with grade III to V VUR (6.8 percentage points compared with 5.4 percentage points for children with grade I to II VUR and 1.8 percentage points for children without VUR).</fragment>
				</section>
			</summary>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210600</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>In children with grade III and IV VUR, data from a Swedish trial demonstrated medical or surgical treatment was more effective than surveillance alone in reducing the risk of febrile UTIs and renal damage in children with grades III and IV VUR.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210601</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>In this study, 203 children between one and two years of age with VUR grade III to IV were randomly assigned to one of three treatment regimens: antibiotic prophylaxis, endoscopic correction, and surveillance with antibiotic treatment for acute infection.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210605</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>This difference was primarily due to the higher rate of UTI in girls compared with that in boys (33 versus 9 percent).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210608</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>New renal damage as detected by dimercaptosuccinic acid (DMSA) renal scan occurred in 0, 9, and 13 percent of patients in the prophylactic, endoscopic, and surveillance groups, respectively.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210612</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>In a retrospective study from a single tertiary center in the United States, 224 of 529 eligible patients with VUR were managed with surveillance alone.</fragment>
				</section>
			</summary>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210615</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>Patients managed off antibiotic therapy were older, had milder VUR, were less likely to present with a febrile UTI, and had lower bladder/bowel dysfunction scores.</fragment>
				</section>
			</summary>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210617</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>As noted above, an ongoing trial in the United States of children with VUR (randomized intervention for VUR [RIVUR] trial) comparing trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis and placebo in 607 children (two months to six years) with grades I to IV VUR following UTI will hopefully add more information that will answer the question of whether the use of prophylactic antibiotics provides any benefits for patients with reflux.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210618</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>Based on the above discussion, prophylactic antibiotics do not appear to be more effective than surveillance alone in reducing the rate of infection or renal scarring in children with mild VUR (grade I and II).</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210621</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>However, it remains uncertain whether intervention is beneficial in preventing recurrent UTI and renal scarring in patients with higher grade VUR.</fragment>
				</section>
			</summary>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H8"/>
			<id>210622</id>
			<summary>
				<section label="Intervention versus surveillance/placebo trials" id="8">
					<fragment>Until data exist that demonstrate conclusively similar renal outcomes (chronic kidney disease and renal scarring) with or without treatment in children with grade III, IV, and V reflux, we continue to treat children with moderate or high-grade VUR.</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H9"/>
			<id>210623</id>
			<summary>
				<section label="Medical versus surgical therapy" id="9">
					<fragment>Data from clinical trials and a systematic review have demonstrated comparable renal outcome in patients treated with either prophylactic antibiotics or surgical correction.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H9"/>
			<id>210624</id>
			<summary>
				<section label="Medical versus surgical therapy" id="9">
					<fragment>The choice of therapy does not impact the renal outcome (ie, renal scarring and impaired renal function) in children with severe bilateral disease who are at increased risk for end-stage renal disease (ESRD) and hypertension (HTN).</fragment>
				</section>
			</summary>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H9"/>
			<id>210625</id>
			<summary>
				<section label="Medical versus surgical therapy" id="9">
					<fragment>This was illustrated in one of the included trials that evaluated medical versus surgical therapy in a group of 52 children with severe bilateral VUR, radiological evidence of renal scarring, and a mean glomerular filtration rate (GFR) of 72.4 mL/min per 1.73 m2.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H9"/>
			<id>210626</id>
			<summary>
				<section label="Medical versus surgical therapy" id="9">
					<fragment>At 10-year follow-up, overall ESRD developed in four patients and HTN in seven patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H9"/>
			<id>210627</id>
			<summary>
				<section label="Medical versus surgical therapy" id="9">
					<fragment>There were no differences in renal function, or in the incidence of HTN and ESRD in patients based upon whether they received medical or surgical management.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H9"/>
			<id>210628</id>
			<summary>
				<section label="Medical versus surgical therapy" id="9">
					<fragment>Based upon the lack of evidence suggesting a difference between medical and surgical therapies, the clinician should provide parents with information regarding the benefits and limitations of the different therapeutic options.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H10"/>
			<id>210631</id>
			<summary>
				<section label="OUR APPROACH" id="10">
					<fragment>Prior to surgical correction for VUR, patients with voiding dysfunction should be identified because inadequately treated voiding dysfunction will lead to failure of surgical VUR correction and an increased risk of urinary tract infection (UTI).</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H11"/>
			<id>210638</id>
			<summary>
				<section label="Grades III to V" id="11">
					<fragment>Our approach is as follows: All patients with grades III to V VUR regardless of age receive antibiotic prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H11"/>
			<id>210640</id>
			<summary>
				<section label="Grades III to V" id="11">
					<fragment>A trial of therapeutic medical intervention should be provided before any surgical intervention is undertaken as the surgical failure rate is significant in patients with persistent voiding dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H11"/>
			<id>210642</id>
			<summary>
				<section label="Grades III to V" id="11">
					<fragment>Grade V reflux in children over six years of age.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H13"/>
			<id>210654</id>
			<summary>
				<section label="Grade I and II" id="13">
					<fragment>Medical therapy - Although several studies have suggested that prophylactic antibiotics may not be an effective intervention in reducing the rate of infection or renal scarring in children with mild VUR, families may choose medical therapy especially in patients who are at risk for urinary tract infections (eg, those with voiding dysfunction) or in infants, who are unable to communicate symptoms in the presence of an infection.</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="Medical therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H13"/>
			<id>210658</id>
			<summary>
				<section label="Grade I and II" id="13">
					<fragment>In particular, prophylactic antibiotic therapy should be considered in patients with voiding dysfunction because of their increased risk of infection.</fragment>
				</section>
			</summary>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="prophylactic antibiotic therapy"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H13"/>
			<id>210659</id>
			<summary>
				<section label="Grade I and II" id="13">
					<fragment>Surgical correction - We do not routinely suggest surgical correction in patients with mild VUR because there is a high likelihood of spontaneous resolution and a low risk of renal scarring.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="Surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210664</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>Mandatory urine cultures and urinalysis are required whenever there are urinary symptoms suggestive of UTI or unexplained fever.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210665</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>Monitoring of reflux is done by either contrast voiding cystourethrogram (VCUG) or radionuclide cystogram (RNC).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210666</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>Although there is little supportive evidence for the timing of follow-up for reflux for patients on medical therapy, evaluation is recommended every 12 to 18 months.</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210667</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>If the reflux is severe in the older child, the interval between imaging studies is increased to 18 months to 2 years because of the lower likelihood of spontaneous resolution.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210669</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>One study has utilized a decision-tree model analysis to determine the optimal timing of follow-up for VCUG in patients treated with prophylactic antibiotics, and recommended that follow-up cystograms can be scheduled every two years in children with grades I and II reflux and every three years in those with grades III or higher.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210673</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>Renal ultrasonography can be used to monitor renal growth and detect the presence of gross scarring.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210674</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>In our practice, renal ultrasounds are routinely performed annually in patients who are medically treated.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210675</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>The American Urology Association (AUA) guidelines suggest that selective monitoring for renal scarring by dimercaptosuccinic acid (DMSA) renal scan is advised for patients at risk for significant abnormalities that may affect their care.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210676</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>In our practice, we routinely obtain DMSA renal scans in patients with grade III to V reflux.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210679</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>DMSA renal scans are also obtained in patients with breakthrough infections, abnormal renal function, or an abnormal renal ultrasound.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H15"/>
			<id>210681</id>
			<summary>
				<section label="Surveillance and medical therapy" id="15">
					<fragment>As an example, a child who is managed by observation may be changed to prophylactic antibiotics, whereas surgical correction may be considered in a child already on antibiotic prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210682</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>There is a paucity of data addressing when medical therapy should be discontinued in patients initially treated with prophylactic antibiotics.</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210683</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>In one retrospective study of 110 children (mean age 5.4 years), prophylactic antibiotics were discontinued in children with vesicoureteral reflux (VUR) who initially presented with febrile urinary tract infection (UTI) after they were toilet-trained and had no evidence of infection or voiding dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210684</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>Febrile UTI developed in 11 patients (10 percent) at a mean 17.2 months after discontinuation of antibiotics, eight of whom had grade III to IV VUR and three of whom had grade II VUR.</fragment>
				</section>
			</summary>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210685</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>Renal ultrasound demonstrated new findings suggestive of scarring in two patients, both of whom had a febrile UTI;</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210686</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>DMSA renal scan confirmed the presence of small cortical defects.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210687</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>Patients who developed subsequent UTIs were more likely to have higher grades of VUR (ie, grades III to V) and developed symptoms of bladder/bowel dysfunction.</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210688</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>In 10 of the 11 patients with UTIs after discontinuation of prophylaxis, surgical correction successfully corrected VUR.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210689</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>These results demonstrate discontinuation of antibiotics is reasonable in infection-free patients with persistent low-grade VUR following toilet-training, but this group of patients may not have needed the initial medical therapy to prevent recurrent infection and scarring.</fragment>
				</section>
			</summary>
			<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210690</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>In another retrospective study of 185 patients with VUR who discontinued antibiotics (mean age 6.2 years), 55 developed UTIs (30 percent) at a mean follow-up of two years.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210691</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>This study was unable to identify any clinical parameter that was predictive of a UTI after discontinuation of prophylactic antibiotics.</fragment>
				</section>
			</summary>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210693</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>This is reflected by some variation between two authors' approach as follows: In both our practices, we continue medical therapy until there is resolution or diminishment of reflux to grade I level in children with VUR who do not have bladder and bowel dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H25151731"/>
			<id>210695</id>
			<summary>
				<section label="Discontinuation of medical therapy" id="25151731">
					<fragment>Both authors maintain medical therapy in children with bladder and bowel dysfunction until there is significant improvement in both voiding symptoms and severity of reflux.</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H16"/>
			<id>210698</id>
			<summary>
				<section label="Surgical therapy" id="16">
					<fragment>Although some studies suggest that it is not necessary to document resolution after open surgical repair, it is our practice to document success of the surgery by a postoperative VCUG or RNC in patients who have undergone surgical correction.</fragment>
				</section>
			</summary>
			<category term="C0374711" scheme="gov.nih.nlm.semanticType.topp" label="surgical repair"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="document"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H17"/>
			<id>210700</id>
			<summary>
				<section label="up" id="17">
					<fragment>Following the resolution of VUR either spontaneously or surgically, long-term follow-up should be provided because of the association of VUR with significant renal sequelae.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H17"/>
			<id>210701</id>
			<summary>
				<section label="up" id="17">
					<fragment>The AUA guidelines suggest annual assessments, which include measurements of growth (height and weight) and blood pressure, and urinalysis to detect proteinuria or bacteria, through adolescence.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H17"/>
			<id>210702</id>
			<summary>
				<section label="up" id="17">
					<fragment>Families should be aware of the potential complications of hypertension, impaired renal function, and the increased risk of VUR in first-degree relatives.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H17"/>
			<id>210704</id>
			<summary>
				<section label="up" id="17">
					<fragment>DMSA renal scan is the most sensitive measure for detecting renal scarring.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H17"/>
			<id>210705</id>
			<summary>
				<section label="up" id="17">
					<fragment>Renal ultrasound is not as sensitive in detecting renal scars as DMSA scan, and as a result has not been as useful in follow-up.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210716</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Current treatment is based upon the long-held view that vesicoureteral reflux (VUR), when combined with urinary tract infection (UTI), is a risk factor for renal scarring, hypertension, and chronic kidney disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210717</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Over the past 30 to 40 years, therapy has been directed towards preventing the reflux of infected urine, thereby reducing renal injury.</fragment>
				</section>
			</summary>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210718</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>It remains unknown precisely how beneficial the treatment of children with VUR is because renal outcome data of patients treated for VUR compared with those who receive no treatment (surveillance) are lacking.</fragment>
				</section>
			</summary>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210719</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Our management is based upon the currently available data, prevention of pyelonephritis, likelihood of renal scarring (which is dependent upon the severity of reflux), the likelihood of spontaneous resolution of VUR, and patient/family preference.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210720</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Patients with VUR may also have voiding dysfunction and should be screened for this condition.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210722</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>We suggest all children with grades III through V reflux be treated because they are at greatest risk for recurrent UTI, renal scarring, and hypertension.</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210723</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>An alternative approach to therapeutic VUR intervention is a surveillance regimen of prompt treatment with intercurrent episodes of UTI.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210724</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Children with grade I to II reflux are at the lowest risk for renal scarring.</fragment>
				</section>
			</summary>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210730</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Medical treatment consists of prophylactic antibiotic therapy with trimethoprim-sulfamethoxazole, trimethoprim alone, or nitrofurantoin.</fragment>
				</section>
			</summary>
			<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="prophylactic antibiotic therapy"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210733</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>We suggest surgical rather than medical therapy in the following group of patients who are unlikely to have spontaneous resolution of their reflux and are at risk for renal scarring.</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210737</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Grade V reflux in children over six years of age.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210739</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Patients who are treated medically or by observation require mandatory urine cultures whenever there are symptoms suggestive of UTI or unexplained fever, and monitoring by radionuclide cystogram for the continued presence of VUR.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210740</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>In our practice, yearly renal ultrasonography is performed in patients who are medically treated, and dimercaptosuccinic acid (DMSA) renal scan is performed in patients with ultrasound results that suggest renal scarring or poor renal growth, those with recurrent UTI, and patients with Grade III through V VUR.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6095#H19"/>
			<id>210742</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Families should be aware of the association of VUR with increased risk of hypertension and chronic kidney disease.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Long-term management and prevention of urinary tract infections in children</title>
		<category term="C0310298" scheme="gov.nih.nlm.semanticType.phsu" label="task"/>
		<category term="C0052509" scheme="gov.nih.nlm.semanticType.aapp" label="asking"/>
		<category term="C0216442" scheme="gov.nih.nlm.semanticType.orch" label="caffeine"/>
		<category term="C0282090" scheme="gov.nih.nlm.semanticType.phsu" label="laxatives"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
		<category term="C0282090" scheme="gov.nih.nlm.semanticType.phsu" label="laxatives"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0453273" scheme="gov.nih.nlm.semanticType.phsu" label="cranberry"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0453273" scheme="gov.nih.nlm.semanticType.phsu" label="cranberry"/>
		<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
		<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
		<category term="C1970989" scheme="gov.nih.nlm.semanticType.topp" label="bladder catheterization"/>
		<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="Trimethoprim"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="Trimethoprim-sulfamethoxazole"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0453273" scheme="gov.nih.nlm.semanticType.phsu" label="cranberry"/>
		<id>6066</id>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H3"/>
			<id>210152</id>
			<summary>
				<section label="Recurrent symptoms" id="3">
					<fragment>Breakthrough UTI are most common in girls.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H3"/>
			<id>210155</id>
			<summary>
				<section label="Recurrent symptoms" id="3">
					<fragment>Families of young children with UTI should receive instruction about the risk of recurrent UTI and be advised to seek medical attention promptly for fever and/or urinary symptoms.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H3"/>
			<id>210156</id>
			<summary>
				<section label="Recurrent symptoms" id="3">
					<fragment>The evaluation of these episodes should include urinalysis, urine culture, or both.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H4"/>
			<id>210157</id>
			<summary>
				<section label="Children with VUR" id="4">
					<fragment>The long-term management and follow-up of children with vesicoureteral reflux (VUR) are discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H5"/>
			<id>210158</id>
			<summary>
				<section label="Children with bowel and bladder dysfunction" id="5">
					<fragment>An important task in the management of children with UTI, especially those with recurrent UTI, is to identify underlying bowel and bladder dysfunction, which is an important risk factor.</fragment>
				</section>
			</summary>
			<category term="C0310298" scheme="gov.nih.nlm.semanticType.phsu" label="task"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H5"/>
			<id>210159</id>
			<summary>
				<section label="Children with bowel and bladder dysfunction" id="5">
					<fragment>Treatment of bowel and bladder dysfunction reduces the likelihood of UTI recurrences and is associated with faster resolution of VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H5"/>
			<id>210161</id>
			<summary>
				<section label="Children with bowel and bladder dysfunction" id="5">
					<fragment>The first steps in the treatment of bowel and bladder dysfunction include timed voiding (scheduled voids every two to three hours), "double" voiding (asking children to sit and urinate again right after they voided), avoidance of C's (carbonated drinks, caffeine, citrus, chocolate, and food colorants), and/or the use of laxatives for children with constipation.</fragment>
				</section>
			</summary>
			<category term="C0052509" scheme="gov.nih.nlm.semanticType.aapp" label="asking"/>
			<category term="C0216442" scheme="gov.nih.nlm.semanticType.orch" label="caffeine"/>
			<category term="C0282090" scheme="gov.nih.nlm.semanticType.phsu" label="laxatives"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H5"/>
			<id>210162</id>
			<summary>
				<section label="Children with bowel and bladder dysfunction" id="5">
					<fragment>In chronically constipated children, treatment with laxatives has been shown to significantly reduce recurrences of UTI.</fragment>
				</section>
			</summary>
			<category term="C0282090" scheme="gov.nih.nlm.semanticType.phsu" label="laxatives"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H6"/>
			<id>210165</id>
			<summary>
				<section label="PREVENTION OF RECURRENT UTI IN CHILDREN WITHOUT VUR" id="6">
					<fragment>The discussion below focuses on prevention of recurrent urinary tract infection (UTI) in children who do not have vesicoureteral reflux (VUR), urinary obstruction, or bowel and bladder dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H7"/>
			<id>210167</id>
			<summary>
				<section label="Surveillance cultures" id="7">
					<fragment>Routine surveillance cultures for asymptomatic children after their first UTI should not be performed.</fragment>
				</section>
			</summary>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H7"/>
			<id>210168</id>
			<summary>
				<section label="Surveillance cultures" id="7">
					<fragment>In a study comparing oral and intravenous antibiotics for UTI in children, routine surveillance of asymptomatic children did not enhance identification of true UTI episodes.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H7"/>
			<id>210169</id>
			<summary>
				<section label="Surveillance cultures" id="7">
					<fragment>Further, treatment of patients who have bacteriuria without symptoms is unproven and may be harmful.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H8"/>
			<id>210170</id>
			<summary>
				<section label="Prophylaxis" id="8">
					<fragment>Several randomized trials have evaluated the benefit of prophylactic antibiotics in preventing recurrent UTI in children, but most studies included only children with VUR.</fragment>
				</section>
			</summary>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H8"/>
			<id>210172</id>
			<summary>
				<section label="Prophylaxis" id="8">
					<fragment>A meta-analysis of individual data restricted to young children 2 to 24 months of age without VUR did not detect a benefit for prophylaxis in preventing recurrence.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H8"/>
			<id>210174</id>
			<summary>
				<section label="Prophylaxis" id="8">
					<fragment>two trials restricted enrollment to children with a first UTI and one trial included &lt;30 percent of children with recurrent UTI.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H8"/>
			<id>210175</id>
			<summary>
				<section label="Prophylaxis" id="8">
					<fragment>Thus, although available data suggest that routine prophylactic antibiotics are not beneficial after a first UTI in children without VUR, there are few data to guide care of children with frequent recurrent UTIs.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H8"/>
			<id>210176</id>
			<summary>
				<section label="Prophylaxis" id="8">
					<fragment>We suggest antimicrobial prophylaxis in children without vesicoureteral reflux (VUR) who have frequent recurrent UTIs (three febrile UTIs in six months or four total UTIs in one year).</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H8"/>
			<id>210180</id>
			<summary>
				<section label="Prophylaxis" id="8">
					<fragment>The management of children with VUR is discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H9"/>
			<id>210181</id>
			<summary>
				<section label="Cranberry juice" id="9">
					<fragment>We do not routinely suggest cranberry juice for the prevention of recurrent UTI in children.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0453273" scheme="gov.nih.nlm.semanticType.phsu" label="cranberry"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H9"/>
			<id>210183</id>
			<summary>
				<section label="Cranberry juice" id="9">
					<fragment>Meta-analysis of two studies limited to children with recurrent UTI also found no benefit.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H9"/>
			<id>210184</id>
			<summary>
				<section label="Cranberry juice" id="9">
					<fragment>Although cranberry juice in moderation is unlikely to be harmful, excessive intake may contribute to dental caries, diarrhea, and obesity.</fragment>
				</section>
			</summary>
			<category term="C0453273" scheme="gov.nih.nlm.semanticType.phsu" label="cranberry"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H11"/>
			<id>210195</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="11">
					<fragment>Families of young children with urinary tract infection (UTI) should receive instruction about the risk of recurrent UTI and be advised to seek medical attention promptly for fever and/or urinary symptoms.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H11"/>
			<id>210196</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="11">
					<fragment>The evaluation for episodes of fever and/or urinary symptoms should include a properly collected urine specimen (using bladder catheterization in children who are not toilet trained) which is then sent for urinalysis, urine culture, or both.</fragment>
				</section>
			</summary>
			<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
			<category term="C0184958" scheme="gov.nih.nlm.semanticType.topp" label="toilet"/>
			<category term="C1970989" scheme="gov.nih.nlm.semanticType.topp" label="bladder catheterization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H11"/>
			<id>210198</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="11">
					<fragment>Routine surveillance cultures in asymptomatic children after their first UTI are unnecessary.</fragment>
				</section>
			</summary>
			<category term="C0733511" scheme="gov.nih.nlm.semanticType.hlca" label="surveillance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H11"/>
			<id>210199</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="11">
					<fragment>We suggest antimicrobial prophylaxis in children without vesicoureteral reflux (VUR) who have frequent recurrent UTIs (three febrile UTIs in six months or four total UTIs in one year).</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H11"/>
			<id>210200</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="11">
					<fragment>Trimethoprim-sulfamethoxazole or nitrofurantoin may be used for prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="Trimethoprim"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="Trimethoprim-sulfamethoxazole"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H11"/>
			<id>210204</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="11">
					<fragment>We do not routinely suggest cranberry juice for the prevention of recurrent UTI in children.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0453273" scheme="gov.nih.nlm.semanticType.phsu" label="cranberry"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6066#H11"/>
			<id>210205</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="11">
					<fragment>The long-term management and follow-up of children with vesicoureteral reflux are discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Presentation, diagnosis, and clinical course of vesicoureteral reflux</title>
		<category term="C0185003" scheme="gov.nih.nlm.semanticType.topp" label="closure"/>
		<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
		<category term="C0963447" scheme="gov.nih.nlm.semanticType.orch" label="mm"/>
		<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0871311" scheme="gov.nih.nlm.semanticType.hlca" label="screening test"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C0963447" scheme="gov.nih.nlm.semanticType.orch" label="mm"/>
		<category term="C0963447" scheme="gov.nih.nlm.semanticType.orch" label="mm"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
		<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0963447" scheme="gov.nih.nlm.semanticType.orch" label="mm"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0589121" scheme="gov.nih.nlm.semanticType.hlca" label="follow-up visit"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C2744791" scheme="gov.nih.nlm.semanticType.orch" label="CKD"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C2744791" scheme="gov.nih.nlm.semanticType.orch" label="CKD"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0808232" scheme="gov.nih.nlm.semanticType.topp" label="therapeutic interventions"/>
		<category term="C2744791" scheme="gov.nih.nlm.semanticType.orch" label="CKD"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C1572381" scheme="gov.nih.nlm.semanticType.phsu" label="no data"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
		<category term="C0808232" scheme="gov.nih.nlm.semanticType.topp" label="therapeutic intervention"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<id>6094</id>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H3"/>
			<id>210221</id>
			<summary>
				<section label="Primary VUR" id="3">
					<fragment>The intravesical ureter length may be genetically dictated, which may explain the increased incidence in family members of patients with VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H4"/>
			<id>210225</id>
			<summary>
				<section label="Secondary VUR" id="4">
					<fragment>Secondary VUR is a result of abnormally high pressure in the bladder that results in failure of the closure of the UVJ during bladder contraction.</fragment>
				</section>
			</summary>
			<category term="C0185003" scheme="gov.nih.nlm.semanticType.topp" label="closure"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H4"/>
			<id>210227</id>
			<summary>
				<section label="Secondary VUR" id="4">
					<fragment>The degree and chronicity of obstruction can influence the severity of VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H4"/>
			<id>210229</id>
			<summary>
				<section label="Secondary VUR" id="4">
					<fragment>None of the data subsequently discussed are applicable to patients with secondary vesicoureteral reflux.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H6"/>
			<id>210240</id>
			<summary>
				<section label="GENETICS" id="6">
					<fragment>There is a strong genetic predisposition for primary vesicoureteral reflux (VUR) as documented by a systematic review of the literature that reported prevalence rates of 27.4 percent for siblings of a patient with VUR, and 35.7 percent for children of an affected parent.</fragment>
				</section>
			</summary>
			<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H6"/>
			<id>210243</id>
			<summary>
				<section label="GENETICS" id="6">
					<fragment>Support for a strong genetic component was also demonstrated by a study of siblings from multiple gestation births that found a higher VUR rate in identical twins (12 out of 15 twin sets, 80 percent) compared with fraternal twins (11 out of 31 twin sets, 35 percent).</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H6"/>
			<id>210247</id>
			<summary>
				<section label="GENETICS" id="6">
					<fragment>however, this gene does not appear to have a causative role in humans.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H6"/>
			<id>210248</id>
			<summary>
				<section label="GENETICS" id="6">
					<fragment>Genes that may play a role in familial VUR include those that encode SLIT2 protein and its receptor ROBO2, which play key roles in the formation of the ureter.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H6"/>
			<id>210249</id>
			<summary>
				<section label="GENETICS" id="6">
					<fragment>In one study, whole genome linkage and association in 320 families with at least two affected siblings failed to detect any association with six candidate genes (AGTR2, HNF1B, PAX2, RET, ROBO2, and UPKA3).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H6"/>
			<id>210250</id>
			<summary>
				<section label="GENETICS" id="6">
					<fragment>The authors conclude that a major locus may not be associated with VUR within affected European families.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210271</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>This variability is primarily due to differences in the definition of prenatal hydronephrosis and the indications for and timing of postnatal evaluation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210273</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>In the larger of the systematic reviews conducted by the American Urological Association (AUA), prenatal hydronephrosis was defined as a renal pelvic diameter (RPD) &gt;=4 mm during the second trimester and &gt;=7 mm during the third trimester.</fragment>
				</section>
			</summary>
			<category term="C0963447" scheme="gov.nih.nlm.semanticType.orch" label="mm"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210275</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>RPD was not predictive of VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210281</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>The extent of the neonatal evaluation required for infants prenatally diagnosed with hydronephrosis is controversial.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210283</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>However, one of the reservations for a full diagnostic evaluation is that the diagnosis of VUR is made only by VCUG or radionuclide cystogram (RNC).</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210284</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>Neither test is a benign procedure because of the need for catheterization, and risk of post-procedure urinary tract infection.</fragment>
				</section>
			</summary>
			<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210286</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>Performing these studies in all neonates with antenatal hydronephrosis would subject a large number of patients without VUR to an invasive and costly procedure.</fragment>
				</section>
			</summary>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210287</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>A sensitive and less invasive screening test for VUR is therefore desirable.</fragment>
				</section>
			</summary>
			<category term="C0871311" scheme="gov.nih.nlm.semanticType.hlca" label="screening test"/>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210289</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>The following examples illustrate this controversy: In one retrospective study, almost 90 percent of patients with known VUR (previously detected by VCUG) had one of the following abnormalities on postnatal renal ultrasonography: increased diameter of the renal pelvis of greater than 7 mm, caliceal or ureteral dilatation, pelviureteral wall thickening, absence of renal corticomedullary differentiation, or findings suggestive of renal dysplasia.</fragment>
				</section>
			</summary>
			<category term="C0963447" scheme="gov.nih.nlm.semanticType.orch" label="mm"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210291</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>A second case series of 121 infants with prenatal hydronephrosis also reported that the risk of VUR increased as the postnatal diameter of the renal pelvis increased with a cut-off of 7 mm demonstrating a fair ability to predict VUR.</fragment>
				</section>
			</summary>
			<category term="C0963447" scheme="gov.nih.nlm.semanticType.orch" label="mm"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210292</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>Other studies, principally observational, have reported that 17 to 25 percent of neonates with a normal postnatal renal ultrasound have VUR detected by VCUG.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210293</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>These authors therefore recommended VCUG be performed on all infants with prenatal hydronephrosis.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210294</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>These studies, although flawed, provide the rationale for the following two approaches for evaluation of prenatal hydronephrosis: Postnatal renal ultrasound and VCUG are performed for all patients with prenatal hydronephrosis.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210296</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>Postnatal renal ultrasound alone is performed initially in all patients with prenatal hydronephrosis.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210297</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>A VCUG is performed only in patients with abnormalities on a postnatal renal ultrasound or who develop a UTI during observation.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210298</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>In our practice, we use the second two-step approach with an initial screening ultrasound for all patients with prenatal hydronephrosis consistent with the AUA and the European Association of Urology guidelines.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210299</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>VCUG is reserved for those with an abnormal ultrasound, those who develop a UTI on observation, or those who have a family history of VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210300</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>VCUG is performed if there are other prenatally detected renal anomalies that increase the risk of VUR, such as ureteropelvic junction obstruction, ureteral duplication, bladder diverticulum, renal agenesis, renal ectopia, and multicystic dysplastic kidney.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H10"/>
			<id>210301</id>
			<summary>
				<section label="Prenatal presentation" id="10">
					<fragment>If a VCUG is to be performed, the procedure needs to be done in referral centers that have expertise both in catheterization and determination of radiation exposure in infants.</fragment>
				</section>
			</summary>
			<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
			<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H11"/>
			<id>210303</id>
			<summary>
				<section label="Our diagnostic approach" id="11">
					<fragment>As discussed previously, the extent of the evaluation for infants prenatally diagnosed with hydronephrosis is controversial.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H11"/>
			<id>210304</id>
			<summary>
				<section label="Our diagnostic approach" id="11">
					<fragment>In our practice, we use the following approach: Repeat renal ultrasonography postdelivery.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H11"/>
			<id>210308</id>
			<summary>
				<section label="Our diagnostic approach" id="11">
					<fragment>If the VCUG is normal and the hydronephrosis is grade 3 or 4 or greater that 12 mm, a functional renal scan with Tc99mMAG3 is suggested to detect possible obstruction.</fragment>
				</section>
			</summary>
			<category term="C0963447" scheme="gov.nih.nlm.semanticType.orch" label="mm"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H11"/>
			<id>210309</id>
			<summary>
				<section label="Our diagnostic approach" id="11">
					<fragment>If the postnatal renal ultrasonography is normal or demonstrates mild hydronephrosis, we repeat renal sonography two or three months later.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H11"/>
			<id>210310</id>
			<summary>
				<section label="Our diagnostic approach" id="11">
					<fragment>If hydronephrosis persists, a follow-up renal sonogram is performed six months late.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H11"/>
			<id>210311</id>
			<summary>
				<section label="Our diagnostic approach" id="11">
					<fragment>If the hydronephrosis worsens at any state, we proceed to a radionuclide cystogram.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H12"/>
			<id>210313</id>
			<summary>
				<section label="Clinical findings and course" id="12">
					<fragment>There is a male predominance in patients with VUR who present prenatally.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H12"/>
			<id>210314</id>
			<summary>
				<section label="Clinical findings and course" id="12">
					<fragment>In one study of 155 consecutive infants with VUR, 75 percent were males and patients with grade V reflux were almost exclusively male.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H12"/>
			<id>210318</id>
			<summary>
				<section label="Clinical findings and course" id="12">
					<fragment>VUR spontaneously resolved in 29 of 32 patients (91 percent) with low-grade reflux (grades I to III).</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H12"/>
			<id>210319</id>
			<summary>
				<section label="Clinical findings and course" id="12">
					<fragment>In patients with high-grade reflux (grades IV and V), VUR resolved in 2 of 11 patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H12"/>
			<id>210320</id>
			<summary>
				<section label="Clinical findings and course" id="12">
					<fragment>In a second study of 25 patients diagnosed prenatally, VUR resolved in 3 of 10 patients with grade IV or V reflux and in 10 of 15 patients with grade I to III reflux.</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H12"/>
			<id>210321</id>
			<summary>
				<section label="Clinical findings and course" id="12">
					<fragment>In a third study of 115 infants (median age 2.7 months) with high-grade VUR (grades III to V), VUR resolved in 26 percent of these high-grade cases.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H13"/>
			<id>210324</id>
			<summary>
				<section label="Decrease renal parenchyma (scarring)" id="13">
					<fragment>In infants who present prenatally, decrease renal parenchyma formation (eg, renal hypoplasia and dysplasia) is often associated with severe reflux.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H13"/>
			<id>210327</id>
			<summary>
				<section label="Decrease renal parenchyma (scarring)" id="13">
					<fragment>As an example, in the previously mentioned study, 3 of the 11 patients with grade IV and V reflux had evidence of primary renal scarring detected by radionuclide renal scan at a median age of three months (range two to eight months) before any clinical evidence of UTI.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H14"/>
			<id>210331</id>
			<summary>
				<section label="Postnatal presentation" id="14">
					<fragment>Postnatal diagnosis of VUR usually is made after a UTI, and less commonly, it is detected after screening of family members (eg, a child or sibling) of an index case.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H14"/>
			<id>210332</id>
			<summary>
				<section label="Postnatal presentation" id="14">
					<fragment>Children with a febrile UTI have a higher risk for abnormalities of the genitourinary tract, including VUR and obstructive uropathy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H14"/>
			<id>210333</id>
			<summary>
				<section label="Postnatal presentation" id="14">
					<fragment>As previously mentioned, the diagnosis of VUR is made only by demonstrating reflux of urine from the bladder to the collecting system either by a VCUG or radionuclide cystogram (RNC).</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H14"/>
			<id>210334</id>
			<summary>
				<section label="Postnatal presentation" id="14">
					<fragment>Among children with VUR who present after an initial UTI, 95 percent will have mild or moderate reflux (ie, grades I to III).</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H14"/>
			<id>210335</id>
			<summary>
				<section label="Postnatal presentation" id="14">
					<fragment>The approach including indications, timing, and choice of modality for imaging in children with UTI is discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H14"/>
			<id>210336</id>
			<summary>
				<section label="Postnatal presentation" id="14">
					<fragment>Children with VUR diagnosed after an initial UTI are also more likely to have dysfunctional voiding.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H16"/>
			<id>210339</id>
			<summary>
				<section label="Clinical course" id="16">
					<fragment>In the majority of cases, VUR will spontaneously resolve, as illustrated by a retrospective study from a single tertiary center that reviewed the outcome of 2462 patients with primary VUR diagnosed between 1998 and 2006.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H16"/>
			<id>210340</id>
			<summary>
				<section label="Clinical course" id="16">
					<fragment>The following findings were noted: VUR resolved spontaneously in 1257 patients (51 percent) at a mean duration of two years.</fragment>
				</section>
			</summary>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H16"/>
			<id>210341</id>
			<summary>
				<section label="Clinical course" id="16">
					<fragment>Factors associated with spontaneous resolution included age of diagnosis under one year of age, lower grades of VUR, prenatal hydronephrosis, and unilateral involvement.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H16"/>
			<id>210344</id>
			<summary>
				<section label="Clinical course" id="16">
					<fragment>Indications for surgery included breakthrough febrile UTI, renal scarring detected by renal radionuclide scan, nonresolution, and parent preference.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H16"/>
			<id>210350</id>
			<summary>
				<section label="Clinical course" id="16">
					<fragment>The oldest group of children (5 to 10 years of age) with bilateral reflux had less than 20 percent resolution over five years.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H16"/>
			<id>210351</id>
			<summary>
				<section label="Clinical course" id="16">
					<fragment>In contrast, there was a 70 percent resolution rate in the youngest group of children (one to two years) with unilateral disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210360</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>Evaluation of scarring by dimercaptosuccinic acid (DMSA) renal scan is more sensitive than ultrasonography.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210364</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>A follow-up DMSA scan performed one to two years later demonstrated renal scarring in 26 percent of the patients including 43 without VUR (19 percent) and 37 with VUR (46 percent).</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210369</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>In another Swedish study of 115 infants (median age at diagnosis 2.7 months) with high grade VUR (ie, grades III, IV and V), renal parenchymal damage detected by either DMSA or MAG3 renal scan was observed in 98 patients (85 percent) at study inclusion;</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210371</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>All patients received antibiotic prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210372</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>At a median follow-up of 5 years, renal parenchymal abnormalities were demonstrated in 103 patients (90 percent).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210377</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>Ninety-one of the 193 patients who participated in the follow-up evaluation had VUR with grades III through V.</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210378</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>Overall, 22 unilateral renal parenchymal defects were detected in 15 percent of 150 patients who underwent ultrasound testing at follow-up: 18 of the defects occurred after the episode of UTI, and all but one of the 22 defects occurred in patients with grade III-V VUR.</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210379</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>In addition, kidney growth retardation was detected by renal ultrasound in five patients (3 percent of tested patients), all of whom had VUR with grade III-V VUR.</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210380</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>At the last follow-up visit, all patients had normal renal function and blood pressure, and no patients had hematuria or proteinuria.</fragment>
				</section>
			</summary>
			<category term="C0589121" scheme="gov.nih.nlm.semanticType.hlca" label="follow-up visit"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210381</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>However, because most patients with grade III-V VUR received medical intervention (eg, antimicrobial prophylaxis) and 45 percent underwent antireflux surgery, it remains uncertain whether or not the favorable clinical outcome was a result of, or despite, active therapeutic measures.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210382</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>In contrast, a retrospective study of 389 Korean children with first febrile urinary tract infection (mean age 14.9 months) did not find an association between reflux grade and scar formation based upon follow-up DMSA scan performed 6 months (range 5 to 7 months) after the urinary tract infection.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H17"/>
			<id>210383</id>
			<summary>
				<section label="Renal scarring and severity of reflux" id="17">
					<fragment>However, other findings in this study were similar to those of the first Swedish study including a 32 percent risk of VUR and an increased likelihood of scarring in patients with VUR compared to those without VUR (50 versus 18 percent).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210389</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>However, this long-held belief that reflux alone can lead to progressive chronic kidney disease due to renal scarring and potentially ESRD, has been increasingly questioned.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210390</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>Another view, as noted previously, is that VUR is not an important risk factor for renal scarring and potential chronic kidney disease (CKD) but is a marker for abnormal renal development, which results in decreased formation of renal parenchyma referred to as primary renal scarring.</fragment>
				</section>
			</summary>
			<category term="C2744791" scheme="gov.nih.nlm.semanticType.orch" label="CKD"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210391</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>Support for this view that VUR does not play a role in renal scar formation but is a marker for abnormal renal development is provided by the following observations: A population-based cohort study of children with first recognized febrile UTI demonstrated that an increased risk for "renal scarring" was principally found in young boys with VUR.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210392</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>These boys did not have a previous history of recurrent UTI and their kidneys were globally small, with smooth renal outlines on radiologic imaging consistent with renal hypoplasia or dysplasia.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210393</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>The authors concluded that children with VUR could be divided into those with primary "scarring" due to due malformation (who are predominately male) and those with acquired scarring.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210394</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>Data from a population-based chronic kidney registry from Italy suggested the primary cause of renal failure in children with VUR was congenital renal hypoplasia or dysplasia.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210396</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>Candidate genes have been identified in animal models that may play a role in the regulation of ureteric and renal development.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210399</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>The rate of reflux-related ESRD has not changed in Australia and New Zealand over the four decades from the 1960s to 1990s despite the change in general clinical practice of proactively identifying children with VUR and treating them with either surgical correction or antibiotic prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210400</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>The viewpoint that CKD results from renal maldevelopment (hypoplasia and dysplasia) associated with VUR has led to questioning the utility of any regimen directed at identifying or treating VUR.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C2744791" scheme="gov.nih.nlm.semanticType.orch" label="CKD"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210401</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>Although there are limited data comparing the outcome of children with VUR who receive treatment (either medical or surgical) to those who receive no directed intervention, the results do not conclusively demonstrate whether or not therapeutic interventions affect long-term renal outcome.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0808232" scheme="gov.nih.nlm.semanticType.topp" label="therapeutic interventions"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210402</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>Because of the severity of the potential poor outcome and the paucity of conclusive evidence, we continue to regard VUR as a risk for recurrent pyelonephritis and possible renal scarring.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H18"/>
			<id>210403</id>
			<summary>
				<section label="ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE" id="18">
					<fragment>As a result, until large clinical studies show similar renal outcomes (chronic kidney disease and renal scarring) in children who do not receive treatment for VUR compared to those who do, we continue to suggest imaging studies to detect possible VUR in at-risk children and intervention in those diagnosed with significant VUR.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866720"/>
			<id>210404</id>
			<summary>
				<section label="FURTHER EVALUATION" id="630866720">
					<fragment>Because of the association between vesicoureteral reflux (VUR) and renal scarring, which may lead to chronic kidney disease (CKD), 2010 revised guidelines from the American Urological Association state that an initial evaluation of the child's renal status, growth parameters, and blood pressure should be performed in any child with VUR.</fragment>
				</section>
			</summary>
			<category term="C2744791" scheme="gov.nih.nlm.semanticType.orch" label="CKD"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866720"/>
			<id>210407</id>
			<summary>
				<section label="FURTHER EVALUATION" id="630866720">
					<fragment>In our practice, we incorporate these guidelines in our evaluation of a child with VUR as follows: A careful medical evaluation is performed, which includes measurement of height, weight, and blood pressure.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866720"/>
			<id>210409</id>
			<summary>
				<section label="FURTHER EVALUATION" id="630866720">
					<fragment>Urinalysis to detect proteinuria or pyuria.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866720"/>
			<id>210411</id>
			<summary>
				<section label="FURTHER EVALUATION" id="630866720">
					<fragment>If pyuria or bacteria is present, a urine culture should be obtained to screen for urinary tract infection (UTI).</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866720"/>
			<id>210416</id>
			<summary>
				<section label="FURTHER EVALUATION" id="630866720">
					<fragment>DMSA renal scan may be obtained in patients who are at-risk for scarring.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866948"/>
			<id>210420</id>
			<summary>
				<section label="Screening of family members" id="630866948">
					<fragment>The screening of family members is controversial, with debate concerning the risk and benefits of screening because there are no data on the outcome of treated versus untreated first degree family members (ie, offspring or siblings) of a patient with VUR.</fragment>
				</section>
			</summary>
			<category term="C1572381" scheme="gov.nih.nlm.semanticType.phsu" label="no data"/>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866948"/>
			<id>210421</id>
			<summary>
				<section label="Screening of family members" id="630866948">
					<fragment>However, there is a rate of renal damage of 14 percent in asymptomatic siblings.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866948"/>
			<id>210422</id>
			<summary>
				<section label="Screening of family members" id="630866948">
					<fragment>Unfortunately, a prospective randomized trial that could determine the optimal approach to managing siblings of patients with VUR is highly unlikely.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866948"/>
			<id>210424</id>
			<summary>
				<section label="Screening of family members" id="630866948">
					<fragment>In one study, hypothetical modeling demonstrated a relatively high cost of universal screening with limited benefits in reducing the number of febrile UTI in siblings of children with VUR.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866948"/>
			<id>210427</id>
			<summary>
				<section label="Screening of family members" id="630866948">
					<fragment>The estimated costs and effectiveness of averting febrile UTIs was heavily dependent on the screening age (screening was most cost-effective for children less than one year of age) and the assumption that antibiotic prophylaxis was effective in reducing the risk of UTI.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866948"/>
			<id>210428</id>
			<summary>
				<section label="Screening of family members" id="630866948">
					<fragment>These observations are not supportive of routine screening of siblings of patients with VUR.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866948"/>
			<id>210429</id>
			<summary>
				<section label="Screening of family members" id="630866948">
					<fragment>There appears to be a significant risk of renal scarring in siblings of patients with high grade VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866948"/>
			<id>210430</id>
			<summary>
				<section label="Screening of family members" id="630866948">
					<fragment>In an observational study of 300 siblings of 259 patients with VUR (ie, grades between III and V), almost a quarter of the 212 siblings who underwent DMSA renal scan had evidence of renal scarring.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H630866948"/>
			<id>210431</id>
			<summary>
				<section label="Screening of family members" id="630866948">
					<fragment>In our practice, we screen siblings and children of patients with VUR because of the increased familial incidence of VUR.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210443</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Vesicoureteral reflux (VUR) is the retrograde passage of urine from the bladder into the upper urinary tract.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210444</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Current management is based upon the long-held belief that VUR, when associated with febrile urinary tract infection, is a risk factor for renal scarring that can result in an increased risk of hypertension and chronic kidney disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210445</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>However, this premise has been increasingly questioned with data supporting an alternate viewpoint that VUR does not play a causative role in renal scarring but merely is a marker for abnormal renal development.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210448</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Until such data are available, we continue to regard VUR as a risk factor for recurrent pyelonephritis and possible renal scarring.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210449</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>As a result, we suggest diagnostic evaluation to detect possible VUR in at-risk children and therapeutic intervention in those with clinically significant VUR.</fragment>
				</section>
			</summary>
			<category term="C0808232" scheme="gov.nih.nlm.semanticType.topp" label="therapeutic intervention"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210451</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>The diagnosis of VUR is based upon the demonstration of reflux of urine from the bladder to the upper urinary tract by either contrast voiding cystourethrogram (VCUG) or radionuclide cystogram (RNC).</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210452</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>The severity of VUR is dependent upon the degree of retrograde filling and dilation of the renal collecting system demonstrated by VCUG or RNC.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210462</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>In our practice, postnatal renal ultrasound alone is performed initially in all patients with prenatal hydronephrosis.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210463</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>A VCUG is performed only in patients with abnormalities on a postnatal renal ultrasound or in those with a strong family history of VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210464</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>An alternate approach is performing postnatal renal ultrasound and VCUG for all patients with prenatal hydronephrosis.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210469</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>We suggest that the following 2010 American Urologic Association guidelines be used in the initial evaluation of children with VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210470</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Medical evaluation including measurements of height, weight, and blood pressure and identifying any patient with symptoms indicative of voiding dysfunction.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210472</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Renal imaging with either renal ultrasound or dimercaptosuccinic acid (DMSA) renal scan.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/6094#H19"/>
			<id>210473</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>We suggest initial screening with sonography for VUR in siblings and children of any patient with VUR.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Urinary tract infections in infants and children older than one month: Acute management, imaging, an</title>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0935699" scheme="gov.nih.nlm.semanticType.phsu" label="eras"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="Antimicrobial"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0308738" scheme="gov.nih.nlm.semanticType.phsu" label="coverage"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0644813" scheme="gov.nih.nlm.semanticType.orch" label="spectrum"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
		<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
		<category term="C0304320" scheme="gov.nih.nlm.semanticType.antb" label="Third-generation cephalosporins"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobials"/>
		<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
		<category term="C0304320" scheme="gov.nih.nlm.semanticType.antb" label="third-generation cephalosporin"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporin"/>
		<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
		<category term="C0455142" scheme="gov.nih.nlm.semanticType.topp" label="intravenous therapy"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
		<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="TMP-SMX"/>
		<category term="C0304317" scheme="gov.nih.nlm.semanticType.antb" label="first-generation cephalosporins"/>
		<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
		<category term="C0050197" scheme="gov.nih.nlm.semanticType.phsu" label="AAP"/>
		<category term="C1962990" scheme="gov.nih.nlm.semanticType.imft" label="Pseudomonas aeruginosa"/>
		<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
		<category term="C0049914" scheme="gov.nih.nlm.semanticType.orch" label="nalidixic acid"/>
		<category term="C0361823" scheme="gov.nih.nlm.semanticType.antb" label="fourth-generation cephalosporins"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C3494403" scheme="gov.nih.nlm.semanticType.hlca" label="tertiary-care"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0038288" scheme="gov.nih.nlm.semanticType.topp" label="sterilization"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="document"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="TMP-SMX"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="anti-inflammatory"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
		<category term="C0432616" scheme="gov.nih.nlm.semanticType.imft" label="anti"/>
		<category term="C0081060" scheme="gov.nih.nlm.semanticType.phsu" label="dexamethasone"/>
		<category term="C0083031" scheme="gov.nih.nlm.semanticType.imft" label="interleukin"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0025815" scheme="gov.nih.nlm.semanticType.horm" label="methylprednisolone"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0308738" scheme="gov.nih.nlm.semanticType.phsu" label="coverage"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
		<category term="C0304320" scheme="gov.nih.nlm.semanticType.antb" label="third-generation cephalosporin"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporin"/>
		<category term="C0361823" scheme="gov.nih.nlm.semanticType.antb" label="fourth-generation cephalosporins"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<id>5991</id>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H3"/>
			<id>209735</id>
			<summary>
				<section label="Goals" id="3">
					<fragment>The goals of treatment for urinary tract infections (UTI) include: Elimination of infection and prevention of urosepsis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H3"/>
			<id>209738</id>
			<summary>
				<section label="Goals" id="3">
					<fragment>Acute management of UTI in children consists of antimicrobial therapy to treat the acute infection and evaluation for possible predisposing factors (eg, urologic abnormalities).</fragment>
				</section>
			</summary>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H4"/>
			<id>209741</id>
			<summary>
				<section label="Decision to hospitalize" id="4">
					<fragment>Most infants older than two months with UTI can be safely managed as outpatients as long as close follow-up is possible.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H5"/>
			<id>209748</id>
			<summary>
				<section label="ANTIBIOTIC THERAPY" id="5">
					<fragment>The effectiveness of antimicrobial therapy for urinary tract infections (UTI) is demonstrated by the change in mortality between the pre- and post-antibiotic eras.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C0935699" scheme="gov.nih.nlm.semanticType.phsu" label="eras"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H5"/>
			<id>209750</id>
			<summary>
				<section label="ANTIBIOTIC THERAPY" id="5">
					<fragment>In contrast, when UTI are appropriately treated with antibiotics, acute complications (eg, renal abscess, death) are uncommon.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H5"/>
			<id>209751</id>
			<summary>
				<section label="ANTIBIOTIC THERAPY" id="5">
					<fragment>Antimicrobial therapy for children with presumed UTI depends upon a number of factors, including the age of the child, severity of illness, presence of vomiting, duration of fever before presentation, underlying medical and/or urologic problems, and the antimicrobial resistance patterns in the community.</fragment>
				</section>
			</summary>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="Antimicrobial"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H6"/>
			<id>209754</id>
			<summary>
				<section label="Empiric therapy" id="6">
					<fragment>Decisions regarding the initiation of empiric antimicrobial therapy for UTI are best made on a case-by-case basis based upon the probability of UTI, which is determined by demographic and clinical factors.</fragment>
				</section>
			</summary>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H6"/>
			<id>209755</id>
			<summary>
				<section label="Empiric therapy" id="6">
					<fragment>We suggest that empiric antimicrobial therapy be initiated immediately after appropriate urine collection in children with suspected UTI and a positive urinalysis.</fragment>
				</section>
			</summary>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H6"/>
			<id>209756</id>
			<summary>
				<section label="Empiric therapy" id="6">
					<fragment>This is particularly true for children who are at increased risk for renal scarring if UTI is not promptly treated, including children who present with: Fever (especially &gt;39oC [102.2oF] or &gt;48 hours).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H7"/>
			<id>209764</id>
			<summary>
				<section label="Choice of agent" id="7">
					<fragment>it accounts for approximately 80 percent of UTI in children.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H7"/>
			<id>209767</id>
			<summary>
				<section label="Choice of agent" id="7">
					<fragment>We recommend that empiric therapy for UTI in infants and children include an antibiotic that provides adequate coverage for E. coli.</fragment>
				</section>
			</summary>
			<category term="C0308738" scheme="gov.nih.nlm.semanticType.phsu" label="coverage"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H7"/>
			<id>209771</id>
			<summary>
				<section label="Choice of agent" id="7">
					<fragment>Increased resistance to extended-spectrum cephalosporins (cefotaxime, ceftazidime, cefepime), has been reported in children receiving prophylactic antibiotics.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C0644813" scheme="gov.nih.nlm.semanticType.orch" label="spectrum"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H7"/>
			<id>209772</id>
			<summary>
				<section label="Choice of agent" id="7">
					<fragment>Third-generation cephalosporins (eg, cefpodoxime, cefixime, cefdinir, ceftibuten, cefotaxime, ceftriaxone) and aminoglycosides (eg, gentamicin, amikacin) are appropriate first-line agents for empiric treatment of UTI in children.</fragment>
				</section>
			</summary>
			<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
			<category term="C0304320" scheme="gov.nih.nlm.semanticType.antb" label="Third-generation cephalosporins"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H7"/>
			<id>209773</id>
			<summary>
				<section label="Choice of agent" id="7">
					<fragment>However, these drugs are not effective in treating Enterococcus and should not be used as monotherapy for patients in whom enterococcal UTI is suspected (eg, those with a urinary catheter in place, instrumentation of the urinary tract, or an anatomical abnormality).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H7"/>
			<id>209775</id>
			<summary>
				<section label="Choice of agent" id="7">
					<fragment>Hydration status and renal function should be assessed in patients who are treated with aminoglycosides.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209776</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>Most children older than two months of age who are not vomiting can be treated with orally administered antimicrobials.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobials"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209779</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>We suggest a third-generation cephalosporin (eg, cefixime cefdinir, ceftibuten) as the first-line oral agent in the treatment of UTI in children without genitourinary abnormalities.</fragment>
				</section>
			</summary>
			<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
			<category term="C0304320" scheme="gov.nih.nlm.semanticType.antb" label="third-generation cephalosporin"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209780</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>In a randomized, controlled trial of 306 children 1 to 24 months of age with a febrile UTI, oral therapy with cefixime for 14 days was as effective as intravenous therapy with cefotaxime for three days followed by oral therapy with cefixime.</fragment>
				</section>
			</summary>
			<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
			<category term="C0455142" scheme="gov.nih.nlm.semanticType.topp" label="intravenous therapy"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209783</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>Oral amoxicillin-clavulanate (50 mg/kg per day in three divided doses) also was shown to be as effective as parenteral therapy followed by oral therapy in a multicenter, randomized trial.</fragment>
				</section>
			</summary>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209785</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>In a child with a penicillin and cephalosporin allergy, treatment with trimethoprim-sulfamethoxazole (TMP-SMX), or ciprofloxacin (if the local resistance rates to TMP-SMX are known to be high) and close follow-up of the antimicrobial sensitivity results is a reasonable strategy.</fragment>
				</section>
			</summary>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
			<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209791</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>Amoxicillin and ampicillin are not routinely recommended for empiric therapy because of the high rate of resistance of E. coli.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209792</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>Similarly, amoxicillin-clavulanate, first-generation cephalosporins (eg, cephalexin), and TMP-SMX should be used with caution because of the increasing rates of resistance to these drugs in some communities.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="TMP-SMX"/>
			<category term="C0304317" scheme="gov.nih.nlm.semanticType.antb" label="first-generation cephalosporins"/>
			<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209796</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>Ciprofloxacin should not be used as a first-line agent.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209797</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>The American Academy of Pediatrics (AAP) Committee on Infectious Diseases recommends that the use of ciprofloxacin for UTI in children be limited to UTI caused by Pseudomonas aeruginosa or other multidrug-resistant, gram-negative bacteria.</fragment>
				</section>
			</summary>
			<category term="C0050197" scheme="gov.nih.nlm.semanticType.phsu" label="AAP"/>
			<category term="C1962990" scheme="gov.nih.nlm.semanticType.imft" label="Pseudomonas aeruginosa"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H8"/>
			<id>209798</id>
			<summary>
				<section label="Oral therapy" id="8">
					<fragment>Oral agents that are excreted in the urine but do not achieve therapeutic serum concentrations (eg, nalidixic acid, nitrofurantoin) should not be used to treat UTI in febrile infants and young children in whom renal involvement is likely because parenchymal and serum concentrations may be insufficient to treat pyelonephritis or urosepsis.</fragment>
				</section>
			</summary>
			<category term="C0028156" scheme="gov.nih.nlm.semanticType.phsu" label="nitrofurantoin"/>
			<category term="C0049914" scheme="gov.nih.nlm.semanticType.orch" label="nalidixic acid"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H9"/>
			<id>209799</id>
			<summary>
				<section label="Parenteral therapy" id="9">
					<fragment>Third- or fourth-generation cephalosporins (eg, cefotaxime, ceftriaxone, cefepime) and aminoglycosides (eg, gentamicin) are appropriate first-line parenteral agents for empiric treatment of UTI in children.</fragment>
				</section>
			</summary>
			<category term="C0361823" scheme="gov.nih.nlm.semanticType.antb" label="fourth-generation cephalosporins"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
			<category term="10" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H9"/>
			<id>209804</id>
			<summary>
				<section label="Parenteral therapy" id="9">
					<fragment>Ampicillin should be included if enterococcal UTI is suspected.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H10"/>
			<id>209812</id>
			<summary>
				<section label="Recent antibiotic exposure" id="10">
					<fragment>Recent exposure to antibiotics, whether for treatment of an infection or as antimicrobial prophylaxis, is an important consideration in the choice of empiric antibiotic therapy.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H624406996"/>
			<id>209813</id>
			<summary>
				<section label="Recurrent UTI" id="624406996">
					<fragment>Review of the antimicrobial susceptibilities of the most recent urinary pathogens can be helpful in choosing empiric therapy for children with recurrent UTI.</fragment>
				</section>
			</summary>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H11"/>
			<id>209814</id>
			<summary>
				<section label="Duration of therapy" id="11">
					<fragment>In a systematic review, short course antimicrobial therapy (two to four days) was as effective as standard duration (7 to 14 days) therapy in eradicating bacteria in children with suspected lower urinary tract infection (ie, afebrile children).</fragment>
				</section>
			</summary>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H11"/>
			<id>209815</id>
			<summary>
				<section label="Duration of therapy" id="11">
					<fragment>However, little evidence is available to guide duration of antimicrobial therapy in children with febrile UTIs.</fragment>
				</section>
			</summary>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H11"/>
			<id>209816</id>
			<summary>
				<section label="Duration of therapy" id="11">
					<fragment>A multicenter trial, sponsored by the National Institutes of Health, is being conducted to determine the efficacy of short-course therapy for UTI in children.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H11"/>
			<id>209818</id>
			<summary>
				<section label="Duration of therapy" id="11">
					<fragment>In the meantime, we suggest a longer course of therapy for febrile children (usually 10 days) and a short course of therapy (three to five days) for immune competent children presenting without fever.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H13"/>
			<id>209821</id>
			<summary>
				<section label="Clinical response" id="13">
					<fragment>In a review of 288 children younger than two years who were admitted to a tertiary-care children's hospital with febrile UTI, 89 percent were afebrile within 48 hours of antimicrobial therapy.</fragment>
				</section>
			</summary>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="C3494403" scheme="gov.nih.nlm.semanticType.hlca" label="tertiary-care"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H14"/>
			<id>209826</id>
			<summary>
				<section label="Repeat urine culture" id="14">
					<fragment>Several observational studies suggest there is little utility in repeating the urine culture in children with UTI who are treated with an antibiotic to which their uropathogen is susceptible.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H14"/>
			<id>209827</id>
			<summary>
				<section label="Repeat urine culture" id="14">
					<fragment>Accordingly, it is not necessary to routinely obtain repeat urine cultures during antimicrobial therapy to document sterilization of the urine, provided that the child has had the expected clinical response and the uropathogen is susceptible to the antibiotic that is used for treatment.</fragment>
				</section>
			</summary>
			<category term="C0038288" scheme="gov.nih.nlm.semanticType.topp" label="sterilization"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="document"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H14"/>
			<id>209828</id>
			<summary>
				<section label="Repeat urine culture" id="14">
					<fragment>However, urine cultures should be performed after 48 hours of therapy if the patient fails to respond clinically or if the uropathogen is not susceptible (intermediate or resistant) to the antibiotic that is being used for treatment.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H522686272"/>
			<id>209832</id>
			<summary>
				<section label="Prophylactic antibiotics" id="522686272">
					<fragment>A meta-analysis of individual data in infants and young children (2 to 24 months) without VUR and with VUR of grades I to IV did not detect a benefit for prophylaxis in preventing recurrence.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H522686272"/>
			<id>209833</id>
			<summary>
				<section label="Prophylactic antibiotics" id="522686272">
					<fragment>However, some of the included trials had methodologic problems potentially biasing results toward no effect (eg, insufficient power; lack of blinding; non-stringent diagnostic criteria; inclusion of uncircumcised boys, which limits generalizability to populations where most boys are circumcised; and misclassification of asymptomatic bacteriuria as recurrent UTIs).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H522686272"/>
			<id>209835</id>
			<summary>
				<section label="Prophylactic antibiotics" id="522686272">
					<fragment>the reduction in absolute risk was greatest for children with grade III-V VUR (6.8 percentage points compared with 5.4 percentage points for children with grade I to II VUR and 1.8 percentage points for children without VUR).</fragment>
				</section>
			</summary>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H522686272"/>
			<id>209836</id>
			<summary>
				<section label="Prophylactic antibiotics" id="522686272">
					<fragment>More conclusive evidence on the benefits of antimicrobial prophylaxis is expected from the ongoing randomized intervention for vesicoureteral reflux (RIVUR) trial comparing TMP-SMX prophylaxis and placebo in 607 children (two months to six years) with grade I to IV VUR following UTI.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="TMP-SMX"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H522686272"/>
			<id>209839</id>
			<summary>
				<section label="Prophylactic antibiotics" id="522686272">
					<fragment>However, if a voiding cystourethrogram (VCUG) is performed and demonstrates grade III or higher VUR, we suggest antimicrobial prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H522686272"/>
			<id>209840</id>
			<summary>
				<section label="Prophylactic antibiotics" id="522686272">
					<fragment>The United Kingdom's National Institute for Health and Care Excellence (NICE) guideline for UTI in children indicates that antibiotic prophylaxis should not be routinely recommended in infants and children following their first UTI, but may be warranted after recurrent UTI.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H549886516"/>
			<id>209841</id>
			<summary>
				<section label="ADJUNCTIVE THERAPIES" id="549886516">
					<fragment>Renal parenchymal inflammation during urinary tract infections (UTI) may lead to renal scarring, although the predisposing factors are not well understood.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H549886516"/>
			<id>209842</id>
			<summary>
				<section label="ADJUNCTIVE THERAPIES" id="549886516">
					<fragment>The role of renal parenchymal inflammation in the development of renal scars, and the potential role of anti-inflammatory agents in preventing renal scars has been evaluated in several studies.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="anti-inflammatory"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
			<category term="C0432616" scheme="gov.nih.nlm.semanticType.imft" label="anti"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H549886516"/>
			<id>209843</id>
			<summary>
				<section label="ADJUNCTIVE THERAPIES" id="549886516">
					<fragment>An observational study demonstrated that dexamethasone decreased urinary levels of interleukin-6 and interleukin-8 in children, suggesting a possible role for glucocorticoids in the prevention of scar formation.</fragment>
				</section>
			</summary>
			<category term="C0081060" scheme="gov.nih.nlm.semanticType.phsu" label="dexamethasone"/>
			<category term="C0083031" scheme="gov.nih.nlm.semanticType.imft" label="interleukin"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H549886516"/>
			<id>209845</id>
			<summary>
				<section label="ADJUNCTIVE THERAPIES" id="549886516">
					<fragment>Treatment with methylprednisolone was associated with decreased renal scarring at six months (33 versus 60 percent in the methylprednisolone and placebo groups, respectively) without significant adverse effects, relapse, or recurrence.</fragment>
				</section>
			</summary>
			<category term="C0025815" scheme="gov.nih.nlm.semanticType.horm" label="methylprednisolone"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H549886516"/>
			<id>209846</id>
			<summary>
				<section label="ADJUNCTIVE THERAPIES" id="549886516">
					<fragment>Results of this small study are difficult to generalize because enrollment required 1) performance of a renal scintigram within 48 hours of diagnosis, which was not conducted in all patients, and 2) severe renal involvement in children who were all hospitalized.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H549886516"/>
			<id>209847</id>
			<summary>
				<section label="ADJUNCTIVE THERAPIES" id="549886516">
					<fragment>Additional studies are necessary to confirm these results and to determine the optimum glucocorticoid regimen before adjunctive glucocorticoids are routinely recommended in the treatment of UTI in children.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H880506880"/>
			<id>209849</id>
			<summary>
				<section label="Rationale" id="880506880">
					<fragment>The rationale for imaging in young children with urinary tract infections (UTI) is to identify abnormalities of the genitourinary tract that require additional evaluation or management (eg, obstructive uropathies, dilating vesicoureteral reflux [VUR]).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H880506880"/>
			<id>209850</id>
			<summary>
				<section label="Rationale" id="880506880">
					<fragment>If such abnormalities are detected, steps can be taken to modify the risk of subsequent renal damage (eg, surgical intervention or antibiotic prophylaxis to prevent recurrent UTI).</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H880506880"/>
			<id>209851</id>
			<summary>
				<section label="Rationale" id="880506880">
					<fragment>The ultimate value of detecting anatomic or functional abnormalities of the urinary tract depends upon the effectiveness of the interventions designed to prevent recurrent UTI and renal scarring.</fragment>
				</section>
			</summary>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H880506880"/>
			<id>209853</id>
			<summary>
				<section label="Rationale" id="880506880">
					<fragment>Prompt diagnosis and effective treatment of recurrent febrile UTI and treatment of bowel and bladder dysfunction that predisposes many children to UTI may be more important than identifying anatomic or functional genitourinary abnormalities after the first febrile UTI in preventing renal scarring.</fragment>
				</section>
			</summary>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H17"/>
			<id>209856</id>
			<summary>
				<section label="Ultrasonography" id="17">
					<fragment>RBUS can also identify renal or perirenal abscess or pyonephrosis in children with acute UTI who fail to improve with antimicrobial therapy.</fragment>
				</section>
			</summary>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H17"/>
			<id>209861</id>
			<summary>
				<section label="Ultrasonography" id="17">
					<fragment>Given the potentially large benefit of detecting correctible malformations for a small number of children and the low risk of harm, we suggest RBUS for the following children: Children younger than two years of age with a first febrile UTI.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H17"/>
			<id>209862</id>
			<summary>
				<section label="Ultrasonography" id="17">
					<fragment>Children of any age with recurrent febrile UTIs.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H17"/>
			<id>209863</id>
			<summary>
				<section label="Ultrasonography" id="17">
					<fragment>Children of any age with a UTI who have a family history of renal or urologic disease, poor growth, or hypertension.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H17"/>
			<id>209868</id>
			<summary>
				<section label="Ultrasonography" id="17">
					<fragment>The United Kingdom's National Institute for Health and Care Excellence (NICE) guideline on UTI in children recommends RBUS for infants younger than six months and for children older than six months who have atypical or recurrent UTI.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H973874071"/>
			<id>209873</id>
			<summary>
				<section label="Timing" id="973874071">
					<fragment>In infants and young children with unusually severe illness or failure to improve as expected after initiation of antimicrobial therapy, RBUS should be performed as soon as possible during the acute phase of illness to identify complications (eg, renal or perirenal abscess, pyonephrosis).</fragment>
				</section>
			</summary>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H973874071"/>
			<id>209874</id>
			<summary>
				<section label="Timing" id="973874071">
					<fragment>However, for infants and young children who respond as expected to appropriate antimicrobial therapy, RBUS should be performed after the acute phase (to reduce the risk of false positive results secondary to renal inflammation during the acute episode).</fragment>
				</section>
			</summary>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209876</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>Vesicoureteral reflux (VUR) is the retrograde passage of urine from the bladder into the upper urinary tract.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209877</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>Approximately 40 percent of young children with a first febrile UTI have VUR.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209878</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>The voiding cystourethrogram (VCUG) is the test of choice to establish the presence and degree of VUR.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209882</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>The utility of the routine VCUG in the evaluation of children with UTI has been questioned.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209883</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>The controversy centers on the changing view of the role of VUR in the development of renal damage and progressive kidney disease (VUR is neither necessary nor sufficient for the development of renal scars) and the uncertainty regarding the effectiveness of medical or surgical management of VUR in reducing the risk of renal scarring.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209884</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>The risk of renal scarring is increased in children with VUR compared with children without VUR (41 versus 17 percent in a systematic review) and increases with increasing grades of VUR.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209886</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>Pending results of the ongoing randomized intervention for vesicoureteral reflux (RIVUR) trial comparing trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis and placebo in 600 children (two months to six years) with grade I to IV VUR following UTI, we suggest VCUG to evaluate possible VUR for: Children of any age with two or more febrile UTIs.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0621239" scheme="gov.nih.nlm.semanticType.orch" label="TMP"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209887</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>Children of any age with a first febrile UTI who have a family history of renal or urologic disease;</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209888</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>children with poor growth or hypertension.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209889</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>Urinary tract anomalies are more frequent among children with UTI caused by pathogens other than E. coli.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209890</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>If a VCUG is performed and demonstrates grade III or higher VUR, we suggest antimicrobial prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H18"/>
			<id>209892</id>
			<summary>
				<section label="Voiding cystourethrogram" id="18">
					<fragment>The recommendation is to postpone the VCUG until the second febrile UTI unless there are atypical or complex clinical circumstances or the RBUS reveals hydronephrosis, scarring, or other findings suggestive of high-grade (IV or V) VUR or obstructive uropathy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H973874079"/>
			<id>209905</id>
			<summary>
				<section label="Timing" id="973874079">
					<fragment>To avoid the use of prophylactic antibiotics in children without VUR, we prefer to conduct VCUGs during the last days of antimicrobial therapy or immediately after completion of antimicrobial therapy for UTI.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H19"/>
			<id>209906</id>
			<summary>
				<section label="Renal scintigraphy" id="19">
					<fragment>Renal scintigraphy using dimercaptosuccinic acid (DMSA) can be used to detect acute pyelonephritis and renal scarring in the acute and chronic settings, respectively.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H19"/>
			<id>209909</id>
			<summary>
				<section label="Renal scintigraphy" id="19">
					<fragment>DMSA scans are expensive, invasive, and expose children to radiation (the pediatric effective dose estimate ranges from 0.3 to 3 mSV).</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H19"/>
			<id>209910</id>
			<summary>
				<section label="Renal scintigraphy" id="19">
					<fragment>The role of renal scintigraphy in the management of children with acute UTI is controversial.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H19"/>
			<id>209915</id>
			<summary>
				<section label="Renal scintigraphy" id="19">
					<fragment>Furthermore, since most young febrile children with UTI have pyelonephritis and a positive DMSA, this strategy may lead to identification of a large number of children who may or may not be at risk for future UTI.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H19"/>
			<id>209916</id>
			<summary>
				<section label="Renal scintigraphy" id="19">
					<fragment>In a systematic review of 33 studies, approximately 60 percent of children with initial UTI had DMSA scans consistent with acute pyelonephritis in the acute phase of illness, but only 15 percent had renal scarring at follow-up.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H19"/>
			<id>209917</id>
			<summary>
				<section label="Renal scintigraphy" id="19">
					<fragment>It is unclear how to best manage children with positive acute-phase DMSA scan.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H19"/>
			<id>209918</id>
			<summary>
				<section label="Renal scintigraphy" id="19">
					<fragment>Careful clinical follow-up of all children with UTI may obviate the need for routine DMSA.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H19"/>
			<id>209919</id>
			<summary>
				<section label="Renal scintigraphy" id="19">
					<fragment>We suggest not using DMSA in the routine evaluation of children with first UTI.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H19"/>
			<id>209922</id>
			<summary>
				<section label="Renal scintigraphy" id="19">
					<fragment>The NICE guidelines recommend DMSA four to six months after acute infection for children younger than three years with atypical or recurrent UTI and for children older than three years with recurrent UTI.</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H522687481"/>
			<id>209927</id>
			<summary>
				<section label="UP" id="522687481">
					<fragment>Parents of infants and young children who have been treated for a febrile UTI and children with bowel and bladder dysfunction (a risk factor for recurrent UTI) should be instructed to seek prompt evaluation for subsequent febrile illnesses to ensure prompt recognition and treatment of recurrent UTI.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H522687481"/>
			<id>209930</id>
			<summary>
				<section label="UP" id="522687481">
					<fragment>Primary care follow-up for infants and young children who have had a febrile UTI should include regular monitoring of height, weight, and blood pressure.</fragment>
				</section>
			</summary>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H20"/>
			<id>209936</id>
			<summary>
				<section label="PROGNOSIS" id="20">
					<fragment>The short-term outcome of first urinary tract infection (UTI) in children (&lt;19 years) was described in a systematic review of 33 studies, including 4891 children: Twenty-five percent had vesicoureteral reflux (VUR);</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H20"/>
			<id>209938</id>
			<summary>
				<section label="PROGNOSIS" id="20">
					<fragment>VUR was associated with an increased risk of developing acute pyelonephritis (relative risk [RR] 1.5, 95% CI 1.1-1.9) and renal scarring (RR 2.6, 95% CI 1.7-3.9);</fragment>
				</section>
			</summary>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H20"/>
			<id>209940</id>
			<summary>
				<section label="PROGNOSIS" id="20">
					<fragment>Fifteen percent (95% CI 11-18 percent) of children had evidence of renal scarring on follow-up dimercaptosuccinic acid (DMSA) scan (5 to 24 months later);</fragment>
				</section>
			</summary>
			<category term="C0012384" scheme="gov.nih.nlm.semanticType.phsu" label="DMSA"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H20"/>
			<id>209944</id>
			<summary>
				<section label="PROGNOSIS" id="20">
					<fragment>Predicting which children with UTI will develop long-term sequelae remains difficult.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H20"/>
			<id>209946</id>
			<summary>
				<section label="PROGNOSIS" id="20">
					<fragment>The large majority of children with UTI have no long-term sequelae, as illustrated by the following studies: In a study of 111 high-risk girls who were followed for 6 to 32 years after their initial UTI, only seven (6 percent) had decreased glomerular filtration rate (GFR), and none developed chronic kidney disease.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H20"/>
			<id>209947</id>
			<summary>
				<section label="PROGNOSIS" id="20">
					<fragment>In another study of 68 children with history of urographic renal scarring who were followed for 16 to 26 years after their index UTI, median GFR and mean 24-hour ambulatory blood pressure were no different in children with and without urographic renal scarring.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H20"/>
			<id>209948</id>
			<summary>
				<section label="PROGNOSIS" id="20">
					<fragment>No child developed chronic kidney disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H20"/>
			<id>209949</id>
			<summary>
				<section label="PROGNOSIS" id="20">
					<fragment>In a study of 226 children with UTI followed for one to 41 years, two developed chronic kidney disease that appeared to be attributable to the UTIs.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H20"/>
			<id>209950</id>
			<summary>
				<section label="PROGNOSIS" id="20">
					<fragment>The prognosis for children with nonfebrile UTI is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209961</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Most children with urinary tract infection (UTI) can be managed as outpatients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209962</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Indications for hospitalization may include age &lt;2 months, immunocompromised patient, vomiting or inability to tolerate oral medication, lack of outpatient follow-up, and failure to respond to outpatient therapy.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209963</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Empiric antimicrobial therapy immediately after appropriate urine collection is warranted in children with suspected UTI and a positive urinalysis.</fragment>
				</section>
			</summary>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209964</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>This is particularly true for young children with fever (especially if &gt;39oC [102.2oF] or &gt;48 hours), ill appearance, costovertebral angle tenderness, known immune deficiency, or known urologic abnormality.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209965</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>We recommend that empiric therapy for UTI in children include an antibiotic that provides adequate coverage for Escherichia coli.</fragment>
				</section>
			</summary>
			<category term="C0308738" scheme="gov.nih.nlm.semanticType.phsu" label="coverage"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209967</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>We suggest a third-generation cephalosporin (eg, cefixime, cefdinir, ceftibuten) as the first-line oral agent in the treatment of UTI in children without genitourinary abnormalities.</fragment>
				</section>
			</summary>
			<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
			<category term="C0304320" scheme="gov.nih.nlm.semanticType.antb" label="third-generation cephalosporin"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209969</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Third- or fourth-generation cephalosporins (eg, cefotaxime, ceftriaxone, cefepime) and aminoglycosides (eg, gentamicin) are appropriate first-line parenteral agents for empiric treatment of UTI in children.</fragment>
				</section>
			</summary>
			<category term="C0361823" scheme="gov.nih.nlm.semanticType.antb" label="fourth-generation cephalosporins"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporins"/>
			<category term="10" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209972</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Febrile children are usually treated for 10 days.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209973</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Afebrile children are usually treated for shorter periods (3 to 5 days).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209976</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Renal bladder ultrasonography (RBUS) should be performed as soon as possible to evaluate the presence of renal abscess or surgically correctable anatomic abnormalities or obstruction.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209977</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>We suggest routine RBUS after first febrile UTI in children younger than two years who did not have normal prenatal ultrasonography at a reputable center at &gt;30 to 32 weeks of gestation.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209978</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>We also suggest RBUS for children of any age with recurrent febrile UTIs and children of any age with a first UTI who have poor growth, hypertension, or a family history of renal or urologic disease.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="11" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209979</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>In contrast to earlier suggestions for evaluation after an initial episode, we now suggest voiding cystourethrogram (VCUG) to evaluate possible vesicoureteral reflux (VUR) for children of any age with &gt;=2 febrile UTIs or a first febrile UTI and any of the following: a family history of renal or urologic disease;</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209982</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>The majority of children with UTI have no long-term sequelae.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/5991#H24"/>
			<id>209983</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Prediction of long-term sequelae in children with UTI remains difficult.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
</aggregateKnowledgeResponse>
